, Volume 70, Issue 7, pp 909–918 | Cite as


In Patients with ST-Segment Elevation Myocardial Infarction
Adis Drug Profile


Bivalirudin is a synthetic 20 amino acid polypeptide that directly inhibits both fibrin-bound and soluble thrombin.

In the randomized, open-label, multicentre HORIZONS-AMI trial in patients with ST-segment elevation myocardial infarction (STEMI) who were undergoing primary percutaneous coronary intervention (PCI), compared with unfractionated heparin (UFH) plus a glycoprotein (GP) IIb/IIIa inhibitor, bivalirudin was associated with a significantly lower 30-day rate of net adverse clinical events that was largely due to the significantly lower 30-day rate of non-coronary-artery bypass grafting major bleeding. There was no significant between-group difference in the 30-day rate of major adverse cardiovascular events. These 30-day clinical outcomes were maintained at the 1- and 2-year follow-up.

Bivalirudin, compared with UFH plus a GP IIb/IIIa inhibitor, was associated with lower short- (30-day) and long- (1- and 2-year) term overall and cardiac mortality rates.

Although there was an increased risk of acute stent thrombosis within 24 hours in recipients of bivalirudin compared with UFH plus a GP IIb/IIIa inhibitor, there was no significant between-group difference between 24 hours and 30 days, ≤30 days, ≤1 year or ≤2 years.


  1. 1.
    Kushner FG, Hand M, Smith SC, et al. 2009 Focused updates: ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction (updating the 2004 Guideline and 2007 Focused update) and ACC/ AHA/SCAI guidelines on percutaneous coronary intervention (updating the 2005 guideline and 2007 focused update): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation 2009 Dec 1; 120(22): 2271–306PubMedCrossRefGoogle Scholar
  2. 2.
    Van de Werf F, Bax J, Betriu A, et al. Management of acute myocardial infarction in patients presenting with persistent ST-segment elevation: the Task Force on the Management of ST-Segment Elevation Acute Myocardial Infarction of the European Society of Cardiology. Eur Heart J 2008 Dec; 29(23): 2909–45PubMedCrossRefGoogle Scholar
  3. 3.
    Widimsky P, Wijns W, Fajadet J, et al. Reperfusion therapy for ST elevation acute myocardial infarction in Europe: description of the current situation in 30 countries. Eur Heart J. Epub 2009 Nov 19Google Scholar
  4. 4.
    De Luca G, Marino P. Antithrombotic therapies in primary angioplasty: rationale, results and future directions. Drugs 2008; 68(16): 2325–44PubMedCrossRefGoogle Scholar
  5. 5.
    De Luca G, Marino P. Advances in antithrombotic therapy as adjunct to reperfusion therapies for ST-segment elevation myocardial infarction. Thromb Haemost 2008 Aug; 100(2): 184–95PubMedGoogle Scholar
  6. 6.
    Warkentin TE. Bivalent direct thrombin inhibitors: hirudin and bivalirudin. Best Pract Res Clin Haematol 2004 Mar; 17(1): 105–25PubMedCrossRefGoogle Scholar
  7. 7.
    Bittl JA, Chaitman BR, Feit F, et al. Bivalirudin versus heparin during coronary angioplasty for unstable or post-infarction angina: final report reanalysis of the Bivalirudin Angioplasty Study. Am Heart J 2001 Dec; 142(6): 952–9PubMedCrossRefGoogle Scholar
  8. 8.
    Lincoff AM, Bittl JA, Harrington RA, et al. Bivalirudin and provisional glycoprotein IIb/IIIa blockade compared with heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary intervention: REPLACE-2 randomized trial. JAMA 2003 Feb 19; 289(7): 853–63PubMedCrossRefGoogle Scholar
  9. 9.
    Stone GW, White HD, Ohman EM, et al. Bivalirudin in patients with acute coronary syndromes undergoing percutaneous coronary intervention: a subgroup analysis from the Acute Catheterization and Urgent Intervention Triage strategy (ACUITY) trial. Lancet 2007 Mar 17; 369(9565): 907–19PubMedCrossRefGoogle Scholar
  10. 10.
    Stone GW, Witzenbichler B, Guagliumi G, et al. Bivalirudin during primary PCI in acute myocardial infarction. N Engl J Med 2008 May 22; 358(21): 2218–30PubMedCrossRefGoogle Scholar
  11. 11.
    Rassen JA, Mittleman MA, Glynn RJ, et al. Safety and effectiveness of bivalirudin in routine care of patients undergoing percutaneous coronary intervention. Eur Heart J 2010 Mar; 31(5): 561–72PubMedCrossRefGoogle Scholar
  12. 12.
    The Medicines Company. Summary of product characteristics: Angiox (bivalirudin). Oxfordshire: The Medicines Company, 2009 Nov 20Google Scholar
  13. 13.
    Deeks ED, Curran MP. Bivalirudin: in patients with acute coronary syndromes planned for urgent or early intervention. Drugs 2008; 68(16): 2345–56PubMedCrossRefGoogle Scholar
  14. 14.
    Moen MD, Keating GM, Wellington K. Bivalirudin: a review of its use in patients undergoing percutaneous coronary intervention. Drugs 2005; 65(13): 1869–91PubMedCrossRefGoogle Scholar
  15. 15.
    The Medicines Company. Angiomax® (bivalirudin) for injection: US prescribing information [online]. Available from URL: http://www.angiomax.com [Accessed 2010 Feb 1]
  16. 16.
    Weitz JI, Hudoba M, Massel D, et al. Clot-bound thrombin is protected from inhibition by heparin-antithrombin III but is susceptible to inactivation by antithrombin III-independent inhibitors. J Clin Invest 1990 Aug; 86(2): 385–91PubMedCrossRefGoogle Scholar
  17. 17.
    Nappi J. The biology of thrombin in acute coronary syndromes. Pharmacotherapy 2002; 22 (6 Pt 2): 90S–6SPubMedCrossRefGoogle Scholar
  18. 18.
    Nylander S, Mattsson C. Thrombin-induced platelet activation and its inhibition by anticoagulants with different modes of action. Blood Coagul Fibrinolysis 2003 Feb; 14(2): 159–67PubMedCrossRefGoogle Scholar
  19. 19.
    Leger AJ, Jacques SL, Badar J, et al. Blocking the protease-activated receptor 1-4 heterodimer in platelet-mediated thrombosis. Circulation 2006 Mar 7; 113(9): 1244–54PubMedCrossRefGoogle Scholar
  20. 20.
    Anand SX, Kim MC, Kamran M, et al. Comparison of platelet function and morphology in patients undergoing percutaneous coronary intervention receiving bivalirudin versus unfractionated heparin versus clopidogrel pretreatment and bivalirudin. Am J Cardiol 2007 Aug 1; 100(3): 417–24PubMedCrossRefGoogle Scholar
  21. 21.
    Keating FK, Dauerman HL, Whitaker DA, et al. Increased expression of platelet P-selectin and formation of plateletleukocyte aggregates in blood from patients treated with unfractionated heparin plus eptifibatide compared with bivalirudin. Thromb Res 2006; 118(3): 361–9PubMedCrossRefGoogle Scholar
  22. 22.
    Schneider DJ, Keating F, Sobel BE. Greater inhibitory effects of bivalirudin compared with unfractionated heparin plus eptifibitide on thrombin-induced platelet activation. Coron Artery Dis 2006 Aug; 17(5): 471–6PubMedCrossRefGoogle Scholar
  23. 23.
    Schneider DJ, Sobel BE. Lack of early augmentation of platelet reactivity after coronary intervention in patients treated with bivalirudin. J Thromb Thrombolysis 2009 Jul; 28(1): 6–9PubMedCrossRefGoogle Scholar
  24. 24.
    Ray MJ, Juneja M, Bett N, et al. A comparison of anti coagulation with bivalirudin and provisional GPIIb/IIIa inhibition with unfractionated heparin and mandatory GPIIb/IIIa inhibition during percutaneous coronary intervention in relation to platelet activation and the inhibition of coagulation. EuroIntervention 2009 Aug; 5(3): 330–5PubMedCrossRefGoogle Scholar
  25. 25.
    Busch G, Steppich B, Sibbing D, et al. Bivalirudin reduces platelet and monocyte activation after elective percutaneous coronary intervention. Thromb Haemost 2009 Feb; 101(2): 340–4PubMedGoogle Scholar
  26. 26.
    Sibbing D, Busch G, Braun S, et al. Impact of bivalirudin or unfractionated heparin on platelet aggregation in patients pretreated with 600 mg clopidogrel undergoing elective percutaneous coronary intervention. Eur Heart J 2008 Jun; 29(12): 1504–9PubMedCrossRefGoogle Scholar
  27. 27.
    Kleiman NS, Klem J, Fernandes LS, et al. Pharmacodynamic profile of the direct thrombin antagonist bivalirudin given in combination with the glycoprotein IIb/IIIa antagonist eptifibatide. Am Heart J 2002 Apr; 143(4): 585–93PubMedCrossRefGoogle Scholar
  28. 28.
    Harding SA, Din JN, Sarma J, et al. Promotion of proinflammatory interactions between platelets and monocytes by unfractionated heparin. Heart 2006 Nov; 92(11): 1635–8PubMedCrossRefGoogle Scholar
  29. 29.
    Bates ER. Bivalirudin: an anticoagulant option for percutaneous coronary intervention. Expert Rev Cardiovasc Ther 2004 Mar; 2(2): 153–62PubMedCrossRefGoogle Scholar
  30. 30.
    Fox I, Dawson A, Loynds P, et al. Anticoagulant activity of hirulog™, a direct thrombin inhibitor, in humans. Thromb Haemost 1993 Feb 1; 69(2): 157–63PubMedGoogle Scholar
  31. 31.
    Topol EJ, Bonan R, Jewitt D, et al. Use of a direct anti-thrombin, hirulog, in place of heparin during coronary angioplasty. Circulation 1993 May; 87(5): 1622–9PubMedCrossRefGoogle Scholar
  32. 32.
    Cannon CP, Maraganore JM, Loscalzo J, et al. Anticoagulant effects of hirulog, a novel inhibitor, in patients with coronary artery disease. Am J Cardiol 1993 Apr 1; 71(10): 778–82PubMedCrossRefGoogle Scholar
  33. 33.
    Robson R, White H, Aylward P, et al. Bivalirudin pharmacokinetics and pharmacodynamics: effect of renal function, dose, and gender. Clin Pharmacol Ther 2002 Jun; 71(6): 433–9PubMedCrossRefGoogle Scholar
  34. 34.
    Lincoff AM, Bittl JA, Kleiman NS, et al. Comparison of bivalirudin versus heparin during percutaneous coronary intervention (the randomized evaluation of PCI Linking Angiomax to reduced Clinical Events [REPLACE]-1 trial). Am J Cardiol 2004 May 1; 93(9): 1092–6PubMedCrossRefGoogle Scholar
  35. 35.
    Carswell CI, Plosker GL. Bivalirudin: a review of its potential place in the management of acute coronary syndromes. Drugs 2002; 62(5): 841–70PubMedCrossRefGoogle Scholar
  36. 36.
    Stella J, Stella R, Stella D, et al. The bivalirudin in the management of patients with ST-segment elevation acute myocardial infarction undergoing primary PCI (BIAMI) trial: in-hospital, 30-day, and 6-month results [abstract no A-34]. Cathet Cardiovasc Interv 2006; 67: 751. Plus poster presented at the 29th Annual Scientific Sessions of the Society for Cardiovascular Angiography and Interventions; 2006 May 10–13; Chicago (IL)Google Scholar
  37. 37.
    Mehran R, Lansky AJ, Witzenbichler B, et al. Bivalirudin in patients undergoing primary angioplasty for acute myocardial infarction (HORIZONS-AMI): 1-year results of a randomised controlled trial. Lancet 2009 Oct 3; 374(9696): 1149–59PubMedCrossRefGoogle Scholar
  38. 38.
    Stone GW, for the HORIZONS-AMI Investigators. HORIZONS AMI: two-year follow-up from a prospective randomized trial of heparin plus glycoprotein IIb/IIIa inhibitors vs. bivalirudin and paclitaxel-eluting vs. baremetal stents in STEMI [abstract plus oral presentation]. 21st Annual Scientific Symposium on Transcatheter Cardiovascular Therapeutics; 2009 Sep 21–26; San Francisco (CA)Google Scholar
  39. 39.
    Dudek D, Zmudka K, Witzenbichler B, et al. Impact of advanced age on the safety and effectiveness of bivalirudin in patients with acute myocardial infarction undergoing primary angioplasty: the HORIZONS AMI trial [abstract no. 2900-191]. J Am Coll Cardiol 2008; 51 Suppl. 2 (10): B67Google Scholar
  40. 40.
    Grinfeld L, Belardi J, Lansky A, et al. Impact of gender on the safety and effectiveness of bivalirudin in patients with acute myocardial infarction undergoing primary angioplasty: the HORIZONS-AMI trial [abstract no. 2900-194]. J Am Coll Cardiol 2008 Mar 11; 51 Suppl. 2 (10): B67Google Scholar
  41. 41.
    European Medicines Agency. Angiox-H-562-II-24 assessment report [online]. Available from URL: http://www.ema.europa.eu/humandocs/PDFs/EPAR/angiox/Angiox-H-562-II-24-AR.pdf [Accessed 2010 Apr 1]
  42. 42.
    Sejersten M, Nielsen SL, Engstrom T, et al. Feasibility and safety of prehospital administration of bivalirudin in patients with ST-elevation myocardial infarction. Am J Cardiol 2009 Jun 15; 103(12): 1635–40PubMedCrossRefGoogle Scholar
  43. 43.
    The Medicines Company. European ambulance acute coronary syndrome angiox trial (EUROMAX): clinical study protocol TMC-BIV-08-03 [online]. Available from URL: http://www.sfcardio.fr/cnchg/recherche-clinique/bourse-des…/euromax…/file [Accessed 2010 Feb 10]
  44. 44.
    US National Institutes of Health. Utilisation of Angiox® in European Practice (EURO-vision) [ClinicalTrials.gov identifier NCT01011504]. US National Institutes of Health, Clinical.Trials.gov [online]. Available from URL: http://www.clinicaltrials.gov [Accessed 2010 Feb 10]

Copyright information

© Adis Data Information BV 2010

Authors and Affiliations

  1. 1.Adis, a Wolters Kluwer BusinessMairangi Bay, North Shore 0754, AucklandNew Zealand

Personalised recommendations